Alessio D. F.
- Country
- Italy
- Department
- Neuroscience e salute mentale
Research Overview
- Randomized, Double‑Blind, Placebo‑Controlled 104‑Week Proof‑of‑Concept Study of IV Prasinezumab in GBA‑Mutation Parkinson’s Disease Assessing Cognitive Decline
- Efficacy and Durability of Ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Phase 3 Study
- A Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients with Early Parkinson's Disease
Data & Insights
Has run more than one trial at 6 of 75 partner sites.
Specializations
Movement Disorders
The investigator specializes in treating various forms of neurodegenerative movement disorders, with particular emphasis on Parkinson's disease and its genetic variants, including GBA-associated Parkinson's disease.
- Early-stage Parkinson's disease interventions
- Motor symptom management
- Disease progression monitoring
Their research extends to evaluating novel therapeutic approaches for managing motor symptoms and disease progression.
Autonomic Disorders
The investigator focuses on treating autonomic dysfunction, particularly neurogenic orthostatic hypotension in patients with various underlying neurological conditions.
- Symptomatic orthostatic hypotension
- Multiple System Atrophy complications
- Autonomic system regulation
Their work addresses the challenging symptoms of autonomic dysfunction in neurological disorders.
Rare Neurological Conditions
The investigator has developed expertise in treating rare neurological disorders, including Multiple System Atrophy and Progressive Supranuclear Palsy.
- Atypical parkinsonian syndromes
- Progressive neurological disorders
- Novel therapeutic approaches
Their research involves evaluating innovative treatments for these challenging neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.